Claris Lifesciences, one of the largest sterile injectables pharmaceutical companies in India, has today announced that it has received MHRA approval for its newly commissioned plant (plant 2). This will help in enhancing capacities to grow in the regulated markets, especially the European Union. The company's specialty injectables business saw a growth of 30% in the last quarter.

The company's flagship plant (plant 1) is already approved by MHRA-UK. This is the first regulatory inspection and compliance approval conducted by MHRA-UK in line with the EU GMP regulations for plant 2, this approval is for terminally sterilized products presented in glass ampoules manufactured in Line1 of the plant 2.

Shares of the company gained Rs 8.65, or 4.93%, to trade at Rs 184. The total volume of shares traded was 55,977 at the BSE (9.32 a.m., Thursday).